Atlas Trials

A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)

Clinical trial NCT02257684 · TERMINATED

Trial details

NCT number
NCT02257684
Sponsor
Jazz Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Start date
2014-09-01
Primary completion
2015-02-01
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.